<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0C477DE0-1812-4DAD-87D5-3A51DEBA2A51"><gtr:id>0C477DE0-1812-4DAD-87D5-3A51DEBA2A51</gtr:id><gtr:name>Entebbe District Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93F65D4D-5E08-4949-92D6-65EC36F1E83F"><gtr:id>93F65D4D-5E08-4949-92D6-65EC36F1E83F</gtr:id><gtr:name>University of Zimbabwe</gtr:name><gtr:address><gtr:line1>PO Box MP 167</gtr:line1><gtr:line2>Mount Pleasant</gtr:line2><gtr:line4>Harare</gtr:line4><gtr:line5>Zimbabwe</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Zimbabwe</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AAFDD84D-2B55-4CB3-9F18-EAE513E90820"><gtr:id>AAFDD84D-2B55-4CB3-9F18-EAE513E90820</gtr:id><gtr:name>The AIDS Support Organization (TASO)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1FE9B7FF-1274-4320-ADE0-4E18B9D24C59"><gtr:id>1FE9B7FF-1274-4320-ADE0-4E18B9D24C59</gtr:id><gtr:name>Makerere University College of Health Sciences</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0C477DE0-1812-4DAD-87D5-3A51DEBA2A51"><gtr:id>0C477DE0-1812-4DAD-87D5-3A51DEBA2A51</gtr:id><gtr:name>Entebbe District Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93F65D4D-5E08-4949-92D6-65EC36F1E83F"><gtr:id>93F65D4D-5E08-4949-92D6-65EC36F1E83F</gtr:id><gtr:name>University of Zimbabwe</gtr:name><gtr:address><gtr:line1>PO Box MP 167</gtr:line1><gtr:line2>Mount Pleasant</gtr:line2><gtr:line4>Harare</gtr:line4><gtr:line5>Zimbabwe</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Zimbabwe</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AAFDD84D-2B55-4CB3-9F18-EAE513E90820"><gtr:id>AAFDD84D-2B55-4CB3-9F18-EAE513E90820</gtr:id><gtr:name>The AIDS Support Organization (TASO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FE9B7FF-1274-4320-ADE0-4E18B9D24C59"><gtr:id>1FE9B7FF-1274-4320-ADE0-4E18B9D24C59</gtr:id><gtr:name>Makerere University College of Health Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6DC31837-4293-4838-972E-B70F4401FDE0"><gtr:id>6DC31837-4293-4838-972E-B70F4401FDE0</gtr:id><gtr:firstName>Heiner</gtr:firstName><gtr:surname>Grosskurth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96D43A36-8970-46E6-8DF4-0FA40E944EFC"><gtr:id>96D43A36-8970-46E6-8DF4-0FA40E944EFC</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Munderi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950080931"><gtr:id>857C8FF2-A0EE-400B-9BF1-F6F540B1BC92</gtr:id><gtr:title>HIV Care Research Programme / DART Trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950080931</gtr:grantReference><gtr:abstractText>Effective antiretroviral drugs have been available for some time to treat HIV infection. ART can drastically reduce HIV in the blood and the tissue and reinstall the competence of the bodys immune response, so that patients with advanced HIV disease become free of symptoms and can lead a normal life at least for many years. In industrialised countries, ART is delivered through intensive follow-up by physicians and involves regular sophisticated laboratory investigations, in order to monitor treatment effectiveness and detect possible side effects of ART.|Most African countries have plans (and meanwhile some funding) for the stepwise introduction of ART delivery services. However, in developing countries, and in rural Africa in particular, the number of highly trained health personnel is small, good laboratory support is often non-existent outside of major cities, funds are limited, and most patients live in rural areas or smaller towns and cannot afford long distance travel. Millions of patients are in need of treatment. A key question is therefore whether simplified but effective ART delivery strategies can be developed for the use by district hospitals and rural health centres in Africa.|Another important question is whether it is possible to interrupt ART at certain intervals in order to reduce the frequency of ART related adverse effects and to save drugs (thus making the available drugs accessible to additional patients), without endangering treatment effectiveness or increasing the risk for drug resistance. Research is therefore needed to identify safe strategies for planned (structured) treatment interruptions. |The DART trial, conducted at research centres in Entebbe, Kampala and Harare, is performed to answer these important questions. It is coordinated by the MRC Clinical Trials Unit and the Imperial College in London. Since 2003, more than 3000 consenting study participants have been enrolled to the study and randomised to different ART delivery strategies. The study will continue until 2008.|The term randomisation implies that after the provision of detailed information, consenting study participants are allocated to one of different treatment groups, whereby the allocation occurs by chance, e.g. based on random numbers generated by a computer. This procedure is the recognised gold standard for studies that investigate the effectiveness of new health interventions, and is the only way to avoid the influence of factors that may otherwise lead to bias or confounding which may invalidate research results.|Whilst results of the trial will only become available after its completion in 2008, interim analyses conducted under the supervision of the trials independent Data Safety and Monitoring Board have so far shown that the drug schemes in use have generally led to excellent suppression of the virus in the blood of the majority of the participants and to a drastic improvement of health and a massive reduction in HIV related death rates.|Early in 2006, at one of the regular interim analyses conducted by the studys independent Data Safety and Monitoring Board, it became apparent that comparatively more clinical adverse events had occurred in the structured treatment interruptions (STI) group than in the continuous treatment group of the study. These adverse events were mostly cases of oesophageal candidiasis, and there was no excess mortality in the STI arm as compared to the CT arm. The comparison between STI and continuous ART has been discontinued, and all patients who had been randomised to STI have been moved to continuous ART. The question whether under certain circumstances STI are feasible and effective remains unanswered, and further research in other patient groups is required.</gtr:abstractText><gtr:technicalSummary>Purpose: The DART Trial is an open-label randomised controlled trial to evaluate different strategies for the management and monitoring of antiretroviral therapy (ART) in Africa. It involves two main randomizations and several substudies. The first randomization compares the effectiveness of clinical monitoring only (CMO) with laboratory plus clinical monitoring (LCM). A second randomization was performed to compare the effectiveness of structured treatment interruptions (STI) with continuous ART. The careful evaluation of these management strategies will answer the important question whether simplified but effective ART delivery approaches can be found that will allow to deliver ART to the millions of patients in Africa who live outside of major cities where only few specialised staff and no sophisticated laboratory support are available. Methods: Main DART trial: (i) Adults (18 years and above) with HIV infection, a CD4 cell count of &amp;lt;200 cells/mm3 and no prior ART were eligible for enrolment. Patients were randomised at enrolment to either the CMO or the LCM arm. (ii) The second randomisation included all patients who had been on ART continuously for 48 weeks or 72 weeks, who had attained a CD4 cell count of &amp;gt;300 cells/ mm3 and who had no record of a serious HIV related infection in the preceding 12 weeks. These patients were randomised to continuous ART or to cycles of STI (12 weeks on /12 weeks off ART). The initial ART regimen in patients on the main DART trial at the Entebbe site comprises zidovudine, lamivudine and tenofovir. Substitutions of individual antiretroviral drugs, within the same class, are made when required for toxicity and a second line treatment regimen is available in the event of documented treatment failure. Follow up monitoring with haematologic tests, tests of liver function, tests of renal function and CD4 counts is performed every 12 weeks. Patients are monitored monthly when drugs are also refilled. Results of investigations in the CMO arm are not returned to clinicians unless indicative of a grade 4 adverse event or unless explicitly requested by clinicians to aid patient management. CD4 counts in the CMO arm are monitored independently by a subgroup of the Data Safety and Monitoring Committee (DSMC). Primary end-points for the trial include progression to new WHO stage 4 disease or death and any serious adverse event which is not HIV-related. An end point review committee with an independent chair regularly reviews and confirms all trial end points as they occur. The randomisation to compare the effectiveness of structured treatment interruptions (STI) with continuous ART has been discontinued in 2006 following a recommendation by the DSMC, as it became obvious that the STI schedule was associated with an increase in disease progression compared to continued treatment. All patients in the STI group were changed to continous ART. Substudies: These include e.g. research of the toxicity of abacavir compared with nevirapine, both in combination with zidovudine + lamivudine, as first-line ART; further investigations of the perceived health related quality of life of patients on ART to identify important needs that go beyond the mere biomedical aspects of ART; investigations of the effect of ART on the sexual behaviour of study participants; studies of the pharmacokinetics of certain drugs; virological studies to explore the effectiveness of the treatment schemes used; research on viral resistance to certain types of drugs; or studies of the effects of different ART management strategies on the immune system. Study sites and coordination: The trial is conducted at 3 sites: Entebbe (MRC/UVRI Uganda Research Unit on AIDS), Kampala (Joint Clinical Research Centre) and Harare (University of Zimbabwe); with funding from MRC, DFID and the Rockefeller Foundation. The Entebbe site works in close collaboration with The AIDS Support Organisation (TASO). The study clinic in Entebbe is situated at the pre</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4157748</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint Clinical Research Center, Kampala</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Partnershipt iwth The Joint Clinical Research Centre, Kampala</gtr:description><gtr:id>2264F4DF-3094-4D2B-87AB-0C5603E14A14</gtr:id><gtr:impact>Established relationship and processes for future joint clinical studies in HIV care</gtr:impact><gtr:outcomeId>AB01104D33F-1</gtr:outcomeId><gtr:partnerContribution>Intersite collaboration on implementing the DART clinical study protocol. Provision of diagnostic laboratory services not available at MRC Entebbe Provision of post trial Antiretroviral therapy for DART study participants</gtr:partnerContribution><gtr:piContribution>Joint clinical study protocol implementation activities, including collaboration in virology and basic scince research activities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Makerere University College of Health Sciences</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:department>The Infectious Diseases Institute, Kampala</gtr:department><gtr:description>Partnership with the Infectious Diseases Institute, Kampala</gtr:description><gtr:id>3F0D33CF-15F1-45EF-879B-8CEA5271B0D3</gtr:id><gtr:impact>Ongoing research and training collaboration and capacity to jointly implement future clinical studies in HIV care</gtr:impact><gtr:outcomeId>1E37411FD47-1</gtr:outcomeId><gtr:partnerContribution>Joint activities to implement a common clinical trial protocol. Joint scientific seminar and training activities</gtr:partnerContribution><gtr:piContribution>Contribution to scientific seminars and training activities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of the UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>Support from DfID</gtr:description><gtr:id>16F7E087-EF1B-4244-AB89-5B164EDFA6A2</gtr:id><gtr:impact>Health policy relevant clinical research results which are being disseminated to nationall and international health policy stakeholders</gtr:impact><gtr:outcomeId>C3BFB048CD3-1</gtr:outcomeId><gtr:partnerContribution>Support in dissemination of research findings to Health Policy stakeholders</gtr:partnerContribution><gtr:piContribution>Implentation of funded clinical trial protocol as per agreement, regular communication regarding progress and products of research, acknowledgement of organisational support at every dissemination forum.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Entebbe District Hospital</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Partnership with Entebbe District Hospital</gtr:description><gtr:id>FEA526FF-8B66-4001-BFBC-E8F7E284E8BE</gtr:id><gtr:impact>Inproved HIV patient care services for the Entebbe community</gtr:impact><gtr:outcomeId>E0DE1D47616-1</gtr:outcomeId><gtr:partnerContribution>Entebbe hopsital provided MRC with clinical research clinic premises under a memorandum of understanding. MRC clinical tudy participants have conviniente access to the hospital's admission facility, radiological and surgical services.</gtr:partnerContribution><gtr:piContribution>Creation of infrastructure for effective antiretroviral therapy including establishment of antiretroviral therapy clinic and joint training and consultation</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The AIDS Support Organization (TASO)</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Partnership with The AIDS Support Organisation (TASO), Entebbe Branch</gtr:description><gtr:id>A178D668-9AC4-46DA-A79E-1406F63D3152</gtr:id><gtr:impact>Acceptance and imbedding of MRC research teams and projects in the community. Facilitated communication with community members on MRC clinical research objectives and results</gtr:impact><gtr:outcomeId>53B2684EF5C-1</gtr:outcomeId><gtr:partnerContribution>Source of research participants from the organisations' membership. Contribution of pyschosocial support services to research participants. Contribution of community outreach networks for dissemination of research information and research results</gtr:partnerContribution><gtr:piContribution>Joint provision of HIV clinical care services. Joint development, consultation, training on antiretroviral therapy provision</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Partnership with Imperial College London</gtr:description><gtr:id>5F5010A5-F6AC-4AA1-AD0E-F1337CCB3FED</gtr:id><gtr:impact>Established capacity for central support of multicentre international HIV studies.</gtr:impact><gtr:outcomeId>12F95B43408-1</gtr:outcomeId><gtr:partnerContribution>Logistic Support and coordination services in grant and clinical trial management</gtr:partnerContribution><gtr:piContribution>Logistic support and central coordination of clinical trial and grant management activities</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zimbabwe</gtr:collaboratingOrganisation><gtr:country>Zimbabwe, Republic of</gtr:country><gtr:department>University of Zimbabwe Clinical Research Centre (UZCRC)</gtr:department><gtr:description>Partnership with the University of Zimbabwe Clinical Research Centre, Harare</gtr:description><gtr:id>1E2B26A0-F29A-4662-8F36-FC280D36B502</gtr:id><gtr:impact>Established clinical trial partnership able to implement joint clinical research activities in the future</gtr:impact><gtr:outcomeId>1E83D44433F-1</gtr:outcomeId><gtr:partnerContribution>Implementation of a common clinical trial protocol</gtr:partnerContribution><gtr:piContribution>Scientific exchange, joint training activities, joint research managemnet activities</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of Results to Uganda National ART Guidelines Committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>723F75E3-42A8-4678-98EE-100C8286818C</gtr:id><gtr:impact>A one day workshop where data generated in the ocuntry that are relevant for our national guideline revision. DART study results were a major contribution to the scientific data discussed by the national advisory panel.

DART study results will influence guidance on monitoring of ART in our next revision of the National guidelines</gtr:impact><gtr:outcomeId>p4LVTLFNgLa</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Policy briefing document on DART study results</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>73250D41-1E58-4C34-9DA9-DAD404647094</gtr:id><gtr:impact>A policy briefing document presenting the study results for an audinece of health policy makers; published in December 2009

The impact remains to be seen</gtr:impact><gtr:outcomeId>E099AA50A9C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Director's Lecture at London School of Hygeine and Tropical Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9F8302F3-0046-4FD6-AFC9-3F70CAF8F4D5</gtr:id><gtr:impact>Aproximately 50 postgraduate students of public helath and epidemiolgy at the London School of Hygeine and Tropical Medicine attended the talk on DART results and implications for ART policy in Africa. The results sparked a fair amount of interest, questions and discussion.

A couple of students expressed interest in collaborating with our study group an their research projects.</gtr:impact><gtr:outcomeId>BS1vJeK6MKf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Uganda National Council of Science and Technology</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FBD9AECA-E91C-49C3-91DB-1280F77D4F5E</gtr:id><gtr:impact>National consultative meeting of research and medicines regulators to discuss ethical appropriateness of further trials on cotrimoxazole prophylaxis among HIV infected patients on antiretroviral therapy. We provided data on effect of Cotrimoxazole on haematologic parameters of untreated HIV infected adults.

A call was made for further studies evaluating continued prophylactic treatment with Cotrimoxazole for HIV infected patients on antiretroviral therapy</gtr:impact><gtr:outcomeId>95023512063</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of DART study results to Staff at DfID headquarters</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3B595902-7F26-4798-B7BC-BB5E36E94774</gtr:id><gtr:impact>Presentation of DART study results and history of the study to staff in Research and Policy Departments of DfID, Glasgow and London.

Well receievd, since DfID were major funders of the study. There is interest in follow on support for a study to implement the ART monitoirng startegy tested in DART</gtr:impact><gtr:outcomeId>oD6g6w1n1Gj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination of study results study participants</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4A209C41-88FE-4384-AE3D-9D5FF652E8BC</gtr:id><gtr:impact>All study participants invited to a meeting where results of study were presented and questions on outcomes answered

Patients feel proud to have been partners in this trial whose results will influence access to and quality of treatment for others affected by HIV/AIDS</gtr:impact><gtr:outcomeId>344028D4258</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>WHO workshop on Pharmacovigilance of antiretroviral medicines</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>824AA92C-6D1E-4D46-9A2E-7D6E5E13C048</gtr:id><gtr:impact>One week workshop attended by ART programme managers and Drug regulatory officials from 8 African countries and Ukraine. Taught sessions on clinical toxicity of antiretroviral medicines drew on published data from the DART study and utilised available illustrative patient case hisotories.

Audience appreciated learning from examples and data that have been accumulated in an African treatment population. There is a clear motivation to set up systems to monitor the long term toxicities of antiretroviral medicines in Africa since overall therapeutic experience with these medicines remains limited.</gtr:impact><gtr:outcomeId>CFDF573E532</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Story of DART - a film</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CA0FCECC-9097-40D6-AF6B-34E717211D22</gtr:id><gtr:impact>A film from patients perspective on having HIV infection and participating in a clinical trial. The results were also briefly featured. Broadcast on National Television channels and on the BBC

Raised the profile of the study and gave it a human face. Extended the reach of the study results.</gtr:impact><gtr:outcomeId>C4F801CB70E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Uganda Ministry of Health - HIV Clinical Care Commitee</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>979A0730-3869-4677-A090-62E43515EA91</gtr:id><gtr:impact>Development and revision of National antiretroviral therapy guidelines based on data from a research cohort in Uganda</gtr:impact><gtr:outcomeId>43A9143BA92</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Uganda Ministry of Health National Working Group on Antiretroviral Drug Resistance</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>E7A22EC2-11E6-4E03-8255-CC618679755C</gtr:id><gtr:impact>Participation of PI in leadership of national project to monitor and prevent the emergence of resistance to antiretroviral drugs</gtr:impact><gtr:outcomeId>76026AAB42E</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Guidelines on Antiretroviral therapy in resource limited settings</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>9283A29D-092E-4C41-B5D2-000C518F9ABF</gtr:id><gtr:impact>Novel data on adverse events of specific antiretroviral drugs in an African population</gtr:impact><gtr:outcomeId>D8080F90012</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A7C5E16B-E013-4040-9A9A-40ED9C411E5F</gtr:id><gtr:title>Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c4ae4cbda123b1042157359c2b7125"><gtr:id>72c4ae4cbda123b1042157359c2b7125</gtr:id><gtr:otherNames>Lara AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>0711F397C44</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55BED203-8A4C-4B76-94AC-44F5CBCCEB09</gtr:id><gtr:title>Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a8bde31d95ec586098b2322368ff463"><gtr:id>5a8bde31d95ec586098b2322368ff463</gtr:id><gtr:otherNames>Ndembi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>djYQbqhcKKv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0625224-B61E-4930-A263-2030D0E5760E</gtr:id><gtr:title>Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86639c545eecdfa7889a1cca13b5c01e"><gtr:id>86639c545eecdfa7889a1cca13b5c01e</gtr:id><gtr:otherNames>Gomo ZA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>546dbf7dd61111.89238291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B75CEB7-F3AA-4B74-93D1-B8B7574E2AEC</gtr:id><gtr:title>A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76496409ebd723eb37f62919a49eeb"><gtr:id>4f76496409ebd723eb37f62919a49eeb</gtr:id><gtr:otherNames>Gilks CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16340_20_23437399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>354E0CB1-FD71-44BD-AAC0-8548E557B628</gtr:id><gtr:title>Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>pm_16340_20_21091860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91307119-6E2C-433E-81C9-DC6979F612E5</gtr:id><gtr:title>Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_16340_20_22024517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49BFD4E-8A10-4088-B395-3F33AF317323</gtr:id><gtr:title>Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_16340_20_22972859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC57044B-473A-462D-8DAF-B17A34EA7481</gtr:id><gtr:title>Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7f5f4c8349da86b35e3575dc9bd508e"><gtr:id>c7f5f4c8349da86b35e3575dc9bd508e</gtr:id><gtr:otherNames>Medina Lara A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16340_20_22545079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AD0F391-7FA4-4915-844B-0F273B3EB2A5</gtr:id><gtr:title>Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>NZt9bbDn5Jm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F4356A0-652D-42E2-ACB5-3FCC68CFC924</gtr:id><gtr:title>CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells &amp;lt;200 Cell/?L: The DART Trial STI Substudy.</gtr:title><gtr:parentPublicationTitle>AIDS research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1240</gtr:issn><gtr:outcomeId>pm_16340_20_21490785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>912FCB87-DAE6-46C4-9113-D1B1E095E339</gtr:id><gtr:title>Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051cf62d6d905f0304eb0c4d1af8ba2e"><gtr:id>051cf62d6d905f0304eb0c4d1af8ba2e</gtr:id><gtr:otherNames>Lyagoba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>r7PaVdJ1n4u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C707039B-D813-4777-AF26-0A1774E17A45</gtr:id><gtr:title>Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3351d89d5f121bef6fc5cb4126499a9b"><gtr:id>3351d89d5f121bef6fc5cb4126499a9b</gtr:id><gtr:otherNames>Goodall RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>546dc21703c026.78726601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D88F051D-635C-405E-96C8-C18A8BEBF96E</gtr:id><gtr:title>The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0762bb899ef58b61c34366d087672b9a"><gtr:id>0762bb899ef58b61c34366d087672b9a</gtr:id><gtr:otherNames>Nyanzi-Wakholi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>owSwWVpBigS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59FF9917-1596-4F40-953A-80EEEAE8874B</gtr:id><gtr:title>Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3417d4ce8ff7e6e00ba6e34e64293c2b"><gtr:id>3417d4ce8ff7e6e00ba6e34e64293c2b</gtr:id><gtr:otherNames>DART Virology Group and Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>D15A4525560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>957544C0-B3B5-48B0-9A7A-B0095C6FB62F</gtr:id><gtr:title>Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts &amp;lt; 200 cells/microl.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/300bcd2c5353d921955a498aa2888782"><gtr:id>300bcd2c5353d921955a498aa2888782</gtr:id><gtr:otherNames>DART Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>7B828221D38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DC19520-BB6D-450B-8A02-8DA2F2ADC629</gtr:id><gtr:title>Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af41ba5a001caff9cfc7754a2e495376"><gtr:id>af41ba5a001caff9cfc7754a2e495376</gtr:id><gtr:otherNames>Dart Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>7A344EE9277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7CFA188-AEBC-4322-AFC4-2CF57866D781</gtr:id><gtr:title>Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>j1xTpHhBvPZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FCE3154-2BB2-4E86-9C28-03BA14288019</gtr:id><gtr:title>Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/204b3fba8c82b0d72f21535fc6b103d3"><gtr:id>204b3fba8c82b0d72f21535fc6b103d3</gtr:id><gtr:otherNames>Ssali F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>623457E23FE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B46D7830-A693-4877-AE08-75E7BD7A20C9</gtr:id><gtr:title>Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>ADDE4A2BE09</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7F5A463-676E-4D97-8449-CE2E607198E6</gtr:id><gtr:title>Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96888be17bf947367e44907c170ce926"><gtr:id>96888be17bf947367e44907c170ce926</gtr:id><gtr:otherNames>Kikaire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>FCBF170E0F3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B64E8927-2F3D-4047-B9A0-6CF95D0CF31B</gtr:id><gtr:title>The charms and challenges of antiretroviral therapy in Uganda: the DART experience.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0762bb899ef58b61c34366d087672b9a"><gtr:id>0762bb899ef58b61c34366d087672b9a</gtr:id><gtr:otherNames>Nyanzi-Wakholi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>pm_16340_20_21777081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1F57869-4921-4E60-9FC3-1355707ECED0</gtr:id><gtr:title>High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546dbfef4405b2.87531813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A9A1F41-A258-4087-A427-83F89C4D5517</gtr:id><gtr:title>Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/300bcd2c5353d921955a498aa2888782"><gtr:id>300bcd2c5353d921955a498aa2888782</gtr:id><gtr:otherNames>DART Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>maQeiqCzXbR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26588F95-47E1-4B08-A85A-80587A37DF42</gtr:id><gtr:title>Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f409e6effa963165e88c95c6b2a649eb"><gtr:id>f409e6effa963165e88c95c6b2a649eb</gtr:id><gtr:otherNames>Reid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>8FAE44AC29D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2F4AE47-0910-409B-A0A1-54D19306D0ED</gtr:id><gtr:title>Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14356e9699c962c762a4c6e584b266bc"><gtr:id>14356e9699c962c762a4c6e584b266bc</gtr:id><gtr:otherNames>Gibb DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_16340_20_22615543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39C11D46-F3EC-453F-9F91-123AFBE8669A</gtr:id><gtr:title>Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1132c254e977729416cdedf9f3f7428"><gtr:id>c1132c254e977729416cdedf9f3f7428</gtr:id><gtr:otherNames>Muyingo SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>AC7EFD1DF96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F13BB4F0-E45B-447E-8583-D16F51B5E809</gtr:id><gtr:title>Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>T3i1iCw3bao</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950080931</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>E4AF608A-CDB6-4CE6-AA10-95B3E043E22F</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.1  Organisation and delivery of services</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>